On day 85 ( week 13 ) 37 % ( 11/30 ) of brodalumab subjects and 22 % ( 2/9 ) of placebo subjects achieved ACR20 ; 7 % ( 2/30 ) brodalumab subjects and 11 % ( 1/9 ) of placebo subjects achieved ACR50 ; and 0 % ( 0/30 ) brodalumab subjects and 0 % ( 0/9 ) of placebo subjects achieved ACR70 .